EUVIMEDEUVIMED entdecken
Übersichtsarbeit

GLP-1 agonists: A review for emergency clinicians

Brit Long, Jessica Pelletier, Alex Koyfman, Rachel E Bridwell

The American Journal of Emergency Medicine · 2024

DOI: 10.1016/j.ajem.2024.01.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The American Journal of Emergency Medicine, 2024. Verfasst von Brit Long und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, USA. Electronic address: Brit.long@yahoo.com. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 88 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Glucagon-like peptide 1 (GLP-1) based therapies, including GLP-1 agonists, are currently in use for treatment of diabetes and obesity. However, several complications may occur with their use. OBJECTIVE: This narrative review provides a focused evaluation of GLP-1 agonist therapy and associated complications for emergency clinicians. DISCUSSION: GLP-1 agonists potentiate insulin release and reduce gastric emptying and food intake. These agents have demonstrated significant improvements in glucose control in diabetics and weight loss in obese patients. The two most common agents include subcutaneous semaglutide (Ozempic, approved for type 2 diabetes, and Wegovy, approved for weight loss) and liraglutide (Saxenda, approved for weight loss, and Victoza, approved for type 2 diabetes), though an oral formulation of semaglutide is available (Rybelsus). While these drugs are associated with improved long-term outcomes, there are a variety of associated adverse events. The most common include gastrointestinal (GI) adverse events such as nausea, vomiting, diarrhea, and abdominal pain. Pancreatitis and biliary disease may also occur. Hypersensitivity including injection site reactions have been associated with use, with reports of anaphylaxis and other rashes. Renal adverse events are most commonly associated with severe GI losses. Hypoglycemia may occur when these agents are used with sulfonylureas or insulin. There is also an increased risk of diabetic retinopathy. Due to the current shortage and expense of these medications, many patients have attempted to obtain these medications from non-licensed and unregulated agents, which may be associated with increased risk of serious complications. CONCLUSIONS: An understanding of the indications for GLP-1 agonist use and associated adverse events can assist emergency clinicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansHypoglycemic AgentsGlucagon-Like Peptide 1ObesityWeight LossInsulin

Stichwörter der Autor:innen

Adverse eventComplicationCompoundingDiabetesEndocrineGLP-1 agonistLiraglutideSemaglutideSide effectWeight loss

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide 1Insulin

Autor:innen und Institutionen

  • Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, USA. Electronic address: Brit.long@yahoo.com.
  • Department of Emergency Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Department of Emergency Medicine, UT Southwestern, Dallas, TX, USA.
  • Department of Emergency Medicine, Madigan Army Medical Center, Tacoma, WA, USA.

Zitieren

APA

Long, B., Pelletier, J., Koyfman, A., & Bridwell, R. E. (2024). GLP-1 agonists: A review for emergency clinicians. The American Journal of Emergency Medicine. https://doi.org/10.1016/j.ajem.2024.01.010

Vancouver

Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 agonists: A review for emergency clinicians. The American Journal of Emergency Medicine. 2024. doi:10.1016/j.ajem.2024.01.010

BibTeX
@article{Long2024,
  author = {Long, Brit and Pelletier, Jessica and Koyfman, Alex and Bridwell, Rachel E},
  title = {GLP-1 agonists: A review for emergency clinicians},
  journal = {The American Journal of Emergency Medicine},
  year = {2024},
  doi = {10.1016/j.ajem.2024.01.010}
}
Kostenlos starten →